Meloxicam SBEβCD Composition for Faster Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.
Innovation Solution
Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is administered in conventional formulations, then the drug can be delivered to patients, but its poor aqueous solubility reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers that form inclusion complexes with meloxicam. The cyclodextrin's hydrophobic interior cavity accommodates the meloxicam molecule while the hydrophilic exterior enables aqueous solubility, thus mediating between the drug's lipophilic nature and the need for water-based delivery to improve both bioavailability and onset speed
Solution Approach 2:
The patent modifies the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins. This changes the solubility parameter from poor (conventional) to improved (complexed form), and alters the dissolution rate parameter to achieve faster onset of action while maintaining reliable bioavailability
2Reliability
If cyclodextrins are used to increase solubility of meloxicam, then bioavailability improves, but the formulation complexity increases
Solution Approach 1:
The patent creates a composite material system consisting of cyclodextrin inclusion complexes. This composite approach combines the host cyclodextrin molecule with the guest meloxicam molecule into a single functional entity that provides both solubility enhancement and drug delivery in one formulation component, managing complexity through material composition rather than process complexity
3Reliability
If conventional NSAIDs are used for migraine treatment, then anti-inflammatory effects are provided, but the onset of pain relief is slow
Solution Approach 1:
The cyclodextrin inclusion complex performs preliminary action by pre-solubilizing the meloxicam in an aqueous environment before administration. This preliminary solubilization ensures that the drug is immediately available for absorption upon contact with gastrointestinal fluids, eliminating the lag time associated with conventional formulations and achieving faster onset while preserving anti-inflammatory reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases meloxicam's oral bioavailability and absorption rate, providing rapid and sustained relief from migraine and other pain conditions, reducing the need for rescue medication and improving treatment outcomes.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.